SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why ...

In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in ...

Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA.

However, Waters has announced plans to merge with BD's life science and diagnostics segment in early 2026, which will dilute that interest in that highly regulated end market, going forward. The ...

Even with the HIV prevention waters now dominated by Gilead Science’s Yeztugo (lenacapavir), Merck & Co. is not afraid to swim deeper in. | Even with the HIV prevention waters now dominated by Gilead ...

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed President Trump’s tariffs and their impact on the ...

The Food and Drug Administration (FDA) has accepted the New Drug Application for doravirine/islatravir (DOR/ISL) for adults with virologically-suppressed HIV-1 infection.

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

From cancer breakthroughs to billion-dollar deals, China is reshaping the global drug race--faster than anyone expected.

China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...